Kite Pharma Inc. (NASDAQ:KITE)’s share price traded up 4.5% on Monday . The company traded as high as $63.10 and last traded at $62.87, with a volume of 592,233 shares trading hands. The stock had previously closed at $60.16.

Several equities analysts recently weighed in on the stock. Vetr lowered shares of Kite Pharma from a “hold” rating to a “sell” rating and set a $57.97 target price on the stock. in a report on Monday. Jefferies Group restated a “buy” rating on shares of Kite Pharma in a report on Friday, August 5th. Barclays PLC set a $60.00 target price on shares of Kite Pharma and gave the company a “hold” rating in a report on Tuesday, August 9th. Mizuho set a $80.00 price target on shares of Kite Pharma and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Finally, Maxim Group reaffirmed a “buy” rating and set a $77.00 price target (down previously from $87.00) on shares of Kite Pharma in a research note on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $73.53.

The firm’s market capitalization is $3.10 billion. The firm’s 50 day moving average price is $53.07 and its 200 day moving average price is $49.20.

Kite Pharma (NASDAQ:KITE) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.91) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.21) by $0.30. During the same period in the prior year, the firm earned ($0.26) earnings per share. The business earned $4.80 million during the quarter, compared to the consensus estimate of $4.86 million. The business’s revenue was up 9.1% on a year-over-year basis. On average, analysts expect that Kite Pharma Inc. will post ($5.83) earnings per share for the current year.

In other Kite Pharma news, SVP Jeffrey Wiezorek sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $56.90, for a total value of $85,350.00. Following the completion of the sale, the senior vice president now directly owns 16,367 shares of the company’s stock, valued at $931,282.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Cynthia M. Butitta sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $50.71, for a total transaction of $1,014,200.00. Following the completion of the sale, the chief operating officer now directly owns 105,401 shares of the company’s stock, valued at $5,344,884.71. The disclosure for this sale can be found here.

Other hedge funds have recently bought and sold shares of the company. California Public Employees Retirement System increased its stake in Kite Pharma by 58.8% in the fourth quarter. California Public Employees Retirement System now owns 51,300 shares of the biopharmaceutical company’s stock valued at $3,161,000 after buying an additional 19,000 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Kite Pharma during the fourth quarter valued at about $2,088,000. Rhumbline Advisers increased its stake in Kite Pharma by 10.2% in the fourth quarter. Rhumbline Advisers now owns 28,768 shares of the biopharmaceutical company’s stock valued at $1,773,000 after buying an additional 2,660 shares in the last quarter. Morgan Stanley increased its stake in Kite Pharma by 3.5% in the fourth quarter. Morgan Stanley now owns 21,628 shares of the biopharmaceutical company’s stock valued at $1,332,000 after buying an additional 739 shares in the last quarter. Finally, Mutual of America Capital Management LLC increased its stake in Kite Pharma by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 16,336 shares of the biopharmaceutical company’s stock valued at $1,007,000 after buying an additional 95 shares in the last quarter.

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.